Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
180 Life Sciences Corp
(NQ:
ATNF
)
1.950
-0.050 (-2.50%)
Streaming Delayed Price
Updated: 2:17 PM EDT, May 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about 180 Life Sciences Corp
< Previous
1
2
3
Next >
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Engages Kinexum for Assistance in MAA Submission
January 17, 2023
Via
Investor Brand Network
180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom
January 17, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
Newman Ferrara LLP Investigating Officers and Directors of 180 Life Sciences Corp. (ATNF)
January 10, 2023
From
Newman Ferrara LLP
Via
Business Wire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Is Notified by NASDAQ Exchange of Full Compliance
January 05, 2023
Via
Investor Brand Network
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
January 05, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Review on Molecular Basis of Dupuytren’s Disease
January 04, 2023
Via
Investor Brand Network
180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s Disease
January 04, 2023
From
180 Life Sciences Corp.
Via
GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Releases Shareholder Letter with Corporate Update
December 29, 2022
Via
Investor Brand Network
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders
December 29, 2022
From
180 Life Sciences Corp.
Via
GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Closes on Registered Direct Offering for $6M
December 27, 2022
Via
Investor Brand Network
180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
December 23, 2022
From
180 Life Sciences Corp.
Via
GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Enters into Registered Direct Offering Agreement for $6M Proceeds
December 21, 2022
Via
Investor Brand Network
180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
December 20, 2022
From
180 Life Sciences Corp.
Via
GlobeNewswire
180 Life Sciences Corp. Announces 1-for 20 Reverse Stock Split as Part of Nasdaq Compliance Plan
December 16, 2022
From
180 Life Sciences Corp.
Via
GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Releases Status Update on MHRA Interaction
December 01, 2022
Via
Investor Brand Network
180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren’s Contracture
November 30, 2022
From
180 Life Sciences Corp.
Via
GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Participation in Upcoming Biotech Conference
November 21, 2022
Via
Investor Brand Network
180 Life Sciences to Participate in A.G.P.’s Virtual Biotech Conference to be Held November 30 – December 1, 2022
November 21, 2022
From
180 Life Sciences Corp.
Via
GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Adalimumab Has Promise as Treatment for Early-Stage Dupuytren’s Disease
November 15, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
CORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease
November 15, 2022
From
180 Life Sciences Corp.
Via
GlobeNewswire
Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease
November 15, 2022
From
180 Life Sciences Corp.
Via
GlobeNewswire
Ron Bauer, Author of Exit Plan: How to Raise Money & Go Public, has a book release planned for December 2022
September 29, 2022
Via
Get News
BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Letter to Stockholders
September 26, 2022
Via
Investor Brand Network
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Enrolls First Patient in Early-Stage Frozen Shoulder Trial
August 22, 2022
Via
Investor Brand Network
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Grant Award to the University of Oxford to Conduct Anti-TNF Therapy Trial
July 27, 2022
Via
Investor Brand Network
180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the National Institute for Health and Care Research in the U.K. to Conduct a Clinical Trial in Post Operative Delirium/Cognitive Deficit in a Jointly Funded Program
July 27, 2022
From
180 Life Sciences Corp.
Via
GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Secures $6.5M in Registered Direct Offering
July 21, 2022
Via
Investor Brand Network
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces $6.5M Registered Direct Offering
July 18, 2022
Via
Investor Brand Network
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) CEO Issues Letter to Stockholders
June 23, 2022
Via
Investor Brand Network
Exposures
COVID-19
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Shares Status of Anti-TNF Treatment, Responses from MHRA and FDA
June 15, 2022
Via
Investor Brand Network
Exposures
Product Safety
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.